OBJECTIVE: To study the impact of two @entity1 @entity11 tissue resistance genes @entity8724 and @entity4735 ) on the @entity2903 -based treatment of @entity11 and detect the relationship of their expressions. METHODS: A total of 58 @entity11 @entity1 aged 19 - 68 years old receiving a chemotherapy of @entity2903 were followed up and classified as non-sensitive group (n = 30) and sensitive group (n = 28). Immunohistochemistry was employed to detect the expression rates of @entity8724 and @entity4735 ). And the correlation between the expressions of two genes was analyzed by immunohistochemistry and RT-PCR (reverse transcription-polymerase chain reaction). RESULTS: The expression rates of @entity8724 and @entity4735 ) were 10.71% and 3.57% in the sensitive group and 63.33% and 56.67% in the non-sensitive group. It had an obvious correlation with the expressions of MEGT and @entity4735 ) through an analysis of immunohistochemistry and RT-PCR (both P < 0.01). CONCLUSION: The expressions of @entity8724 and @entity4735 ) in the sensitive group are markedly lower than those in the non-sensitive group. The expression of two genes may be related to @entity5 prognosis. Maybe these two genes have an intrinsic link between their expressions. Both participate in the repair of cellular DNA damage and the formation of @entity5 drug resistance. And the prognosis has obvious relevance.

[Comparison of @entity8724 and ERCC    expression in @entity2903 for the treatment of XXXX drug resistance and their genetic relationship].

@entity1 :: ('9606', 'Species') :: ['human', 'patients'] @entity4735 :: ('2068', 'Gene') :: ['ERCC(2'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity11 :: ('MESH:D005910', 'Disease') :: ['malignant glioma', 'glioma', 'malignant gliomas'] @entity8724 :: ('4255', 'Gene') :: ['MGMT'] @entity2903 :: ('MESH:C047246', 'Chemical') :: ['temozolomide']
@entity11 :: (MESH:D005910,Disease) :: ['malignant glioma']
